Raclopride tartrate
Raclopride tartrate structure
|
Common Name | Raclopride tartrate | ||
|---|---|---|---|---|
| CAS Number | 98185-20-7 | Molecular Weight | 497.32400 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H26Cl2N2O9 | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
Use of Raclopride tartrateRaclopride tartrate is a selective dopamine D2/D3 receptor antagonist with potential antipsychotic effects. Raclopride tartrate binds to D2 and D3 receptors with Kis of 1.8 nM and 3.5 nM, respectively[1][2]. |
| Name | (S)-(-)-3,5-dichloro-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamide L-(+)-tartrate |
|---|---|
| Synonym | More Synonyms |
| Description | Raclopride tartrate is a selective dopamine D2/D3 receptor antagonist with potential antipsychotic effects. Raclopride tartrate binds to D2 and D3 receptors with Kis of 1.8 nM and 3.5 nM, respectively[1][2]. |
|---|---|
| Related Catalog | |
| Target |
D2 Receptor:1.8 nM (Ki) D3 Receptor:3.5 nM (Ki) D4 Receptor:2400 nM (Ki) D1 Receptor:18000 nM (Ki) |
| In Vivo | Raclopride tartrate (0.1, 0.3, or 0.6 mg/kg; IP; 30 min; albino male mice of the OF1 strain) significantly reduces time allocated to attack behavior[2]. |
| References |
[1]. Seeman P, et al. Dopamine receptor pharmacology. Trends Pharmacol Sci. 1994;15(7):264-270. |
| Molecular Formula | C19H26Cl2N2O9 |
|---|---|
| Molecular Weight | 497.32400 |
| Exact Mass | 496.10200 |
| PSA | 176.86000 |
| LogP | 1.12790 |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| RTECS | CV3465000 |
|
Effect of raclopride on dopamine D2 receptor mRNA expression in rat brain.
Neuroscience 47 , 771-779, (1992) Prolonged treatment with dopamine D2 receptor antagonists is known to elevate the density of dopamine D2 receptor binding sites in caudate-putamen and nucleus accumbens in rat and human brain. In this... |
|
|
Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
Psychopharmacology 112 , 389-397, (1993) The effects of chronic treatment with dopamine (DA) D1 and D2 receptor antagonists were evaluated in eight cebus apella monkeys with mild oral dyskinesia after previous haloperidol treatment. SCH 2339... |
|
|
Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents.
Eur. J. Pharmacol. 271 , 167, (1994) S 14506 (1-[-(4-fluorobenzoylamino)ethyl]-4-(7-methoxynaphthyl)piper azine hydrochloride), 8-OH-DPAT ((+/-)-8-hydroxydipropylaminotetralin hydrobromide), clozapine and raclopride were compared in some... |
| (S)-2-[(3,5-dichloro-6-methoxy-2-hydroxybenzamido)methyl]-1-ethylpyrrolidine L-tartrate |
| raclopride tartarate |
| raclopride tartrate |
| (S)-2-[(3,5-dichloro-6-methoxy-2-hydroxybenzamido)methyl]-1-ethylpyrrolidine L-tartrate |
| S(-)-RACLOPRIDE (+)-TARTRATE SALT |